NEWS
- Key Advances in Breast Cancer Treatment: First Half of 2025
- BMS-986238: A New Macrocyclic Peptide-Based PD-L1 Inhibitor
- Camptothecin & Its Derivatives for Cancer Therapy
- FDA Approves First NASH Drug & Other Pipelines in Clinical Trials
- Advances in Macrocyclic Peptide Drug Development
- Upcoming GLP-1 RAs for NASH: A Comprehensive List
- Targeted Therapies for Systemic Lupus Erythematosus (SLE)
- Antibody–Drug Conjugate Payloads: MMAE & MMAF
- Semaglutide vs. Tirzepatide for Obesity
- Click Chemistry Reagents - Azide, Alkyne, DBCO, BCN PEG Products from Biochempeg
